What is Epinex Diagnostics Laboratories?
Epinex Diagnostics Laboratories specializes in the creation of advanced diagnostic tests designed to enhance diabetes management. Their proprietary platform technology leverages immunoassay strips and biosensors to produce unique quantitative tests, particularly for underserved markets. A key offering is the Glycated Albumin-based Monthly Diabetes Test (G1A), which aims to improve patient outcomes and reduce healthcare expenditures by enabling more effective self-management of chronic conditions and fostering better doctor-patient communication.
How much funding has Epinex Diagnostics Laboratories raised?
Epinex Diagnostics Laboratories has raised a total of $4M across 4 funding rounds:
Unspecified
$1.2M
Unspecified
$598K
Private Equity
$2.2M
Debt
$32K
Unspecified (2008): $1.2M, investors not publicly disclosed
Unspecified (2010): $598K, investors not publicly disclosed
Private Equity (2013): $2.2M, investors not publicly disclosed
Debt (2021): $32K featuring PPP
What's next for Epinex Diagnostics Laboratories?
With the recent influx of substantial expansion capital, Epinex Diagnostics Laboratories is strategically positioned for significant scaling. This financing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden market reach for their diagnostic solutions. The company's focus on improving diabetes management through accessible technology suggests a trajectory towards becoming a key player in the point-of-care diagnostics sector, potentially leading to further strategic partnerships or future funding rounds to support global expansion.
See full Epinex Diagnostics Laboratories company page
